An official website of the United States government
These tables are also available in a printable version (PDF, 158 KB).
Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List.
Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors
(Effective Date 1/1/2014)
| ICD-9-CM Code* | Explanation of ICD-9-CM Code |
|---|---|
| 140._ - 172._, 174._ - 209.36, 209.7_ | Malignant neoplasms (excluding category 173), stated or presumed to be primary (of specified sites) and certain specified histologies1 |
| 173.00, 173.09 | Unspecified/other malignant neoplasm of skin of lip |
| 173.10, 173.19 | Unspecified/other malignant neoplasm of eyelid, including canthus |
| 173.20, 173.29 | Unspecified/other malignant neoplasm of ear and external auricular canal |
| 173.30, 173.39 | Unspecified/other malignant neoplasm of skin of other/unspecified parts of face |
| 173.40, 173.49 | Unspecified/other malignant neoplasm of scalp and skin of neck |
| 173.50, 173.59 | Unspecified/other malignant neoplasm of skin of trunk, except scrotum |
| 173.60, 173.69 | Unspecified/other malignant neoplasm of skin of upper limb, including shoulder |
| 173.70, 173.79 | Unspecified/other malignant neoplasm of skin of lower limb, including hip |
| 173.80, 173.89 | Unspecified/other malignant neoplasm of other specified sites of skin |
| 173.90, 173.99 | Unspecified/other malignant neoplasm of skin, site unspecified |
| 225.0 - 225.9 | Benign neoplasm of brain and spinal cord neoplasm |
| 227.3, 227.4 | Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland |
| 228.02 | Hemangioma; of intracranial structures |
| 228.1 | Lymphangioma, any site (Note: Reportable tumors include only lymphangioma of the brain, other parts of nervous system and endocrine gland) |
| 230.0-234.9 | Carcinoma in situ |
| 237.0-237.1 | Neoplasm of uncertain behavior of endocrine glands and nervous system: pituitary gland, craniopharyngeal duct and pineal gland |
| 237.5, 237.6, 237.9 | Neoplasm of uncertain behavior of endocrine glands & nervous system: brain & spinal cord, meninges, endocrine glands & other & unspec. parts of nervous system |
| 238.4 | Polycythemia vera |
| 238.7_ | Other lymphatic and hematopoietic diseases |
| 239.6, 239.7 | Neoplasms of unspecified nature, brain, endocrine glands and other parts of nervous system |
| 273.3 | Macroglobulinemia (Waldenstrom's macroglobulinemia) |
| 277.89 | Other specified disorders of metabolism (Reportable includes terms: Hand-Schuller-Christian disease; histiocytosis (acute)(chronic); histiocytosis X (chronic)) |
1Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant)
NOTE: Cases with these codes should be screened as registry time allows. Experience in the SEER registries has shown that using the Supplemental List increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases.
Supplemental List ICD-9-CM
(Effective Date 1/1/2014)
| ICD-9-CM Code* | Explanation of ICD-9-CM Code |
|---|---|
| 042 | Acquired Immunodeficiency Syndrome (AIDS) Note: Screen 042 for history of cancers with HIV/AIDS |
| 079.51-079.53 | Retrovirus (HTLV, types I, II and 2) |
| 173.01, 173.02 | Basal and squamous cell carcinoma of skin of lip |
| 173.11, 173.12 | Basal and squamous cell carcinoma of eyelid, including canthus |
| 173.21, 173.22 | Basal and squamous cell carcinoma of ear and external auricular canal |
| 173.31, 173.32 | Basal and squamous cell carcinoma of skin of other and unspecified parts of face |
| 173.41, 173.42 | Basal and squamous cell carcinoma of scalp and skin of neck |
| 173.51, 173.52 | Basal and squamous cell carcinoma of skin of trunk, except scrotum |
| 173.61, 173.62 | Basal and squamous cell carcinoma of skin of upper limb, including shoulder |
| 173.71, 173.72 | Basal and squamous cell carcinoma of skin of lower limb, including hip |
| 173.81, 173.82 | Basal and squamous cell carcinoma of other specified sites of skin |
| 173.91, 173.92 | Basal and squamous cell carcinoma of skin, site unspecified |
| 209.40 - 209.69 | Benign carcinoid tumors |
| 210.0 - 229.9 | Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 228.02, 228.1, which are listed in the Reportable list) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
| 235.0-236.99 | Neoplasm of uncertain behavior of adrenal gland, paraganglia and other and unspecified endocrine glands Note: screen for incorrectly coded malignancies or reportable by agreement tumors |
| 237.2-237.4 | Neoplasm of uncertain behavior of adrenal gland, paraganglia and other and unspecified endocrine glands Note: screen for incorrectly coded malignancies or reportable by agreement tumors |
| 237.7_ | Neurofibromatosis and Schwannomatosis |
| 238.0-239.9 | Neoplasms of uncertain behavior (except for 238.4, 238.71-238.79, 239.6, 239.7, which are listed in the reportable list) Note: Screen for incorrectly coded malignancies or reportable by agreement tumors |
| 259.2 | Carcinoid syndrome |
| 273.0 | Polyclonal hypergammaglobulinemia (Note: screen for blood disorders due to neoplasm) |
| 273.1 | Monoclonal gammopathy of undetermined significance (9765/1) Note: Screen for incorrectly coded Waldenstrom macroglobulinemia or progression |
| 273.2 | Other paraproteinemias |
| 273.8, 273.9 | Other and unspecified disorders of plasma protein metabolism Note: includes plasma disorders due to neoplastic disease |
| 275.42 | Hypercalcemia (Note: Includes hypercalcium due to neoplastic disease) |
| 277.88 | Tumor lysis syndrome (following neoplastic chemotherapy) |
| 284.1_ | Pancytopenia (Note: screen for anemia disorder related to neoplasm) |
| 285.22 | Anemia in neoplastic disease |
| 285.3 | Anemia due to antineoplastic chemotherapy |
| 287.39, 287.49, 287.5 | Secondary, other primary and unspecified thrombocytopenia Note: Screen for incorrectly coded thrombocythemia |
| 288.03 | Drug induced neutropenia (note: screen for anemia disorder related to neoplasm) |
| 288.3 | Eosinophilia (Note: Code for eosinophilia (9964/3). Not every case of eosinophilia is with a malignancy. Diagnosis must be "Hypereosonophilic syndrome" to be reportable.) |
| 288.4 | Hemophagocytic syndrome |
| 338.3 | Neoplasm related pain (acute)(chronic) |
| 528.01 | Mucositis due to antineoplastic therapy |
| 530.85 | Barrett's esophagus (High grade dysplasia of esophagus) |
| 569.44 | Dysplasia of anus (Anal intraepithelial neoplasia [AIN I and II]) |
| 602.3 | Dysplasia of prostate (Prostatic intraepithelial neoplasia [PIN I and II]) |
| 622.10-622.12 | Dysplasia of cervix, unspecified and CIN I, CIN II |
| 623.0 | Dysplasia of vagina (Vaginal intraepithelial neoplasia [VAIN I and II] |
| 624.01, 624.02 | Vulvar intraepithelial neoplasia: unspecified, VIN I and VIN II |
| 630 | Hydatidiform mole (Note: benign tumor that can become malignant. If malignant, it should be reported as Choriocarcinoma (9100/3) with malignancy code in 140-209 range) |
| 780.79 | Neoplastic (malignant) related fatigue |
| 785.6 | Enlargement of lymph nodes |
| 789.51 | Malignant ascites |
| 790.93 | Elevated prostate specific antigen (PSA) |
| 793.8_ | Nonspecific (abnormal) findings on radiological & examination of body structure (breast) |
| 795.0_ - 795.1_ | Papanicolaou smear of cervix and vagina with cytologic evidence of malignancy |
| 796.7_ | Abnormal cytologic smear of anus and anal HPV |
| 795.8_ | Abnormal tumor markers; Elevated tumor associated antigens [TAA] |
| 963.1 | Poisoning by primarily systemic agents: antineoplastic and immunosuppressive drugs |
| 990 | Effects of radiation, unspecified (radiation sickness) |
| 999.3_ | Complications due to central venous catheter |
| E858.0 | Accidental poisoning by other drugs: Hormones and synthetic substitutes |
| E858.1 | Accidental poisoning by other drugs: Primary systemic agents |
| E858.2 | Agents primarily affecting blood constituents |
| E873.2 | Failure in dosage, overdose of radiation in therapy (radiation sickness) |
| E879.2 | Overdose of radiation given during therapy (radiation sickness) |
| E930.7 | Adverse reaction of antineoplastic therapy-Antineoplastic antibiotics |
| E932.1 | Adverse reaction to antineoplastic therapy-Androgens and anabolic congeners |
| E933.1 | Adverse effect (poisoning) of immunosuppressive drugs |
| V10.0_ - V10.9_ | Personal history of malignancy Note: Screen for recurrences, subsequent primaries, and/or subsequent treatment |
| V12.41 | Personal history of benign neoplasm of the brain |
| V13.89 | Personal history of unspecified. malignant neoplasm, history of in-situ neoplasm of other site |
| V15.3 | Other personal history presenting hazards to health or (therapeutic) radiation |
| V42.81, V42.82 | Organ or tissue replaced by transplant: Bone marrow, peripheral stem cells |
| V51.0 | Encounter for breast reconstruction following mastectomy |
| V58.0, V58.1_ | Encounter for radiotherapy, chemotherapy, immunotherapy |
| V66.1, V66.2 | Convalescence and palliative care following radiotherapy, chemotherapy |
| V66.7 | Encounter for palliative care |
| V67.1, V67.2 | Follow up examination: following radiotherapy or chemotherapy |
| V71.1 | Observation for suspected malignant neoplasm |
| V76._ | Special screening for malignant neoplasms |
| V86._ | Estrogen receptor positive status [ER+], negative status [ER-] |
| V87.41 | Personal history of antineoplastic chemotherapy |
| V87.43 | Personal history of estrogen therapy |
| V87.46 | Personal history of immunosuppression therapy |
*International Classification of Diseases, 9th Revision, Clinical Modification, Sixth Edition, 2014
